The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors

被引：8
|
作者：
Agboola, Foluso [1 ]
Rind, David M. [1 ]
Walton, Surrey M. [2 ]
Herron-Smith, Serina [1 ]
Quach, Danny [2 ]
Pearson, Steven D. [1 ]
机构：
[1] Inst Clin & Econ Review, Boston, MA 02109 USA
[2] Univ Illinois, Ctr Pharmacoepidemiol & Pharmacoecon Res, Chicago, IL USA
来源：
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY | 2021年 / 27卷 / 05期
关键词：
RECOMBINANT FACTOR-VIII;
D O I：
10.18553/jmcp.2021.27.5.667
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：667 / 673
页数：7
相关论文
共 50 条
  • [21] Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors
    Mahlangu, J.
    Oldenburg, J.
    Paz-Priel, I.
    Negrier, C.
    Niggli, M.
    Mancuso, M. E.
    Schmitt, C.
    Jimenez-Yuste, V.
    Kempton, C.
    Dhalluin, C.
    Callaghan, M. U.
    Bujan, W.
    Shima, M.
    Adamkewicz, J. I.
    Asikanius, E.
    Levy, G. G.
    Kruse-Jarres, R.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (09): : 811 - 822
  • [22] Emicizumab Prophylaxis in Hemophilia A with Inhibitors
    Wada, Hideo
    Matsumoto, Takeshi
    Katayama, Naoyuki
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (22): : 2193 - 2194
  • [23] Emicizumab Prophylaxis in Hemophilia A with Inhibitors
    Oldenburg, Johannes
    Mahlangu, Johnny N.
    Kim, Benjamin
    Schmitt, Christophe
    Callaghan, Michael U.
    Young, Guy
    Santagostino, Elena
    Kruse-Jarres, Rebecca
    Negrier, Claude
    Kessler, Craig
    Valente, Nancy
    Asikanius, Elina
    Levy, Gallia G.
    Windyga, Jerzy
    Shima, Midori
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (09): : 809 - 818
  • [24] Management of Joint Replacement in Hemophilia a with Inhibitors during Emicizumab Prophylaxis
    Santagostino, Elena
    Mancuso, Maria Elisa
    Novembrino, Cristina
    Boscolo, Massimo Anzoletti
    Clerici, Marigrazia
    Pasta, Gianluigi
    Solimeno, Luigi Piero
    Peyvandi, Flora
    BLOOD, 2017, 130
  • [25] Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice
    La Mura, Vincenzo
    Cardinale, Vincenzo
    De Cristofaro, Raimondo
    De Santis, Adriano
    Di Minno, Giovanni
    Fabris, Luca
    Marra, Fabio
    Morisco, Filomena
    Peyvandi, Flora
    Pompili, Maurizio
    Santoro, Cristina
    Zanon, Ezio
    Castaman, Giancarlo
    BLOOD ADVANCES, 2024, 8 (22) : 5725 - 5734
  • [26] Real-World Use of Emicizumab in Patients with Hemophilia with and without Inhibitors
    McCary, Isabella
    Guelcher, Christine
    Kuhn, Jan
    Butler, Regina
    Massey, Gita
    Guerrera, Michael F.
    Ballester, Lance
    Raffini, Leslie J.
    BLOOD, 2019, 134
  • [27] Use of Emicizumab in Patients with Hemophilia a with and without Inhibitors: A Single Center Experience
    Giuffrida, Gaetano
    Nicolosi, Daniela
    Condorelli, Annalisa
    Markovic, Uros
    Di Raimondo, Francesco
    BLOOD, 2021, 138
  • [28] EMICIZUMAB IN PEDIATRIC PATIENTS WITH HEMOPHILIA A WITH AND WITHOUT INHIBITORS - EXPERIENCE OF A PORTUGUESE CENTRE
    Pestana, J. S. G.
    Peixoto, C.
    Camara, C.
    Correia, C. J.
    Felix, J.
    Pires, F.
    Pereira, A.
    Rodrigues, F.
    Afonso, P.
    Rocha, E.
    Catarino, C.
    HAEMOPHILIA, 2023, 29 : 107 - 107
  • [29] Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A
    Long, Brian R.
    Veron, Philippe
    Kuranda, Klaudia
    Hardet, Romain
    Mitchell, Nina
    Hayes, Gregory M.
    Wong, Wing Yen
    Lau, Kelly
    Li, Mingjin
    Hock, M. Benjamin
    Zoog, Stephen J.
    Vettermann, Christian
    Mingozzi, Federico
    Schweighardt, Becky
    MOLECULAR THERAPY, 2021, 29 (02) : 597 - 610
  • [30] Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors
    Sun, Shawn X.
    Wu, Yanyu
    McDermott, Michael
    van Keep, Marjolijn
    BLOOD, 2019, 134
12345